Glucagon and GLP-1 receptor co-agonist
Cotadutide injection
COTA_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.74 (-1.25 to -0.23) | 0.42 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.56 (-1.66 to 0.56) | 0.65 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.96 (-6.15 to 2.52) | 0.63 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.24 (-4.14 to -0.26) | 0.80 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.99 (1.76 to 9.08) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 38.19) | 0.40 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.59 (0.26 to 32.69) | 0.29 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.36 (-7.36 to 2.82) | 0.53 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -2.19 (-8.52 to 5.52) | 0.73 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.53 (1.32 to 12.28) | 0.63 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.74 (1.48 to 13.64) | 0.68 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 9.32 (1.68 to 73.57) | 0.70 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.07 (0.62 to 1.89) | 0.44 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.10 (2.94 to 17.63) | 0.09 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.09 (3.25 to 11.74) | 0.13 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.77 (3.36 to 19.07) | 0.14 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.80 (2.06 to 7.32) | 0.13 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.12 (1.28 to 8.78) | 0.21 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.97 (0.11 to 8.78) | 0.58 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.74 (0.18 to 20.43) | 0.55 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 2.42 (0.53 to 11.51) | 0.46 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 5.43 (0.76 to 52.11) | 0.36 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 13.65 (1.15 to 300) | 0.10 |
Trials
- NCT03555994An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.2018 · 51 randomized · 5 weeks
- NCT03550378A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment2018 · 41 randomized · 4.57 weeks
- NCT03235050A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus2017 · 834 randomized · 54 weeks